Develops gene therapies for serious and life-threatening rare diseases. Utilizes a gene therapy approach that transforms a patient's hematopoietic stem cells. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 35% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 54.4× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 82% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 35% a year on average.
Sales run at $7.0M a year. A small number, but proof the product has real buyers.
There is $143.8M in the vault; even if every debt were paid off, $85.7M would remain.
A loss of $7.9M against $7.0M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.